Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers

Table 2 Differences in response among the two groups

Baseline variable	P-SOX group (n = 28)	SOX group (n = 61)	P value
TRG			0.038
TRG0	4 (14.29%)	3 (4.92%)
TRG1	8 (28.57%)	8 (13.11%)
TRG2	13 (46.43%)	30 (49.18%)
TRG3	3 (10.71%)	20 (32.79%)
Subgroup analysis			0.013a
TRG0/TRG1	12 (42.86%)	11 (18.03%)
TRG2/TRG3	16 (57.14%)	50 (81.97%)
ypT stage			0.272
0	4 (14.29%)	2 (3.23%)
1	1 (3.57%)	3 (4.92%)
2	6 (21.43%)	8 (13.11%)
3	2 (7.14%)	5 (8.20%)
4	15 (53.57%)	43 (70.49%)
ypN stage			0.130
0	11 (39.29%)	12 (19.67%)
1	5 (8.20%)	7 (11.48%)
2	5 (8.20%)	15 (24.59%)
3	7 (25%)	27 (44.26%)
ypM stage			0.099
	26 (92.86%)	48 (78.69%)
	2 (7.14%)	13 (21.31%)
ypTNM stage			0.196
pCR	4 (14.29%)	3 (4.92%)
I	4 (14.29%)	3 (4.92%)
II	4 (14.29%)	12 (19.67%)
III	13 (46.43%)	29 (47.54%)
IV	3 (10.71%)	14 (22.95%)
ypT stage			0.055
T0	4 (14.29%)	2 (3.28%)
T1-T4	24 (85.71%)	59 (96.72%)
ypN stage			0.05a
N0	11 (39.29%)	12 (19.67%)
N1-N3	17 (60.71%)	49 (80.33%)
ypTNM stage			0.130
pCR	4 (14.29%)	3 (4.92%)
I-IV	24 (85.71%)	58 (95.08%)

^aStatistically significant (P < 0.05).

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin; pCR: Pathological complete response; TRG: Tumor regression grade.